Drug Information

Drug General Information
Drug ID
D0MP1M
Former ID
DNCL001970
Drug Name
CERE-110
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [522629]
Company
Ceregene
Target and Pathway
Target(s) Beta-nerve growth factor Target Info Modulator [530834]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Apoptosis
Neurotrophin signaling pathway
Inflammatory mediator regulation of TRP channels
Pathway Interaction Database SHP2 signaling
p75(NTR)-mediated signaling
Neurotrophic factor-mediated Trk receptor signaling
Trk receptor signaling mediated by PI3K and PLC-gamma
Reactome Frs2-mediated activation
ARMS-mediated activation
NRAGE signals death through JNK
p75NTR negatively regulates cell cycle via SC1
PI3K/AKT activation
NADE modulates death signalling
NRIF signals cell death from the nucleus
p75NTR recruits signalling complexes
NF-kB is activated and signals survival
Axonal growth stimulation
WikiPathways SIDS Susceptibility Pathways
MAPK Signaling Pathway
BDNF signaling pathway
Signalling by NGF
NGF signalling via TRKA from the plasma membrane
References
Ref 522629ClinicalTrials.gov (NCT00876863) Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 530834CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.